MétaCan
Menu
← Back to cohort
Record W2907571060

Monitoring the T cell response to spontaneous mammary tumors using a novel transgenic mouse model

2005· article· en· W2907571060 on OpenAlexaff
Erika M. Wall, Katy Milne, Brad H. Nelson

Bibliographic record

VenueCancer Research · 2005
Typearticle
Languageen
FieldImmunology and Microbiology
TopicImmunotherapy and Immune Responses
Canadian institutionsBC Cancer Agency
Fundersnot available
KeywordsCD8BiologyEpitopeT cellImmune systemCytotoxic T cellMHC class IGenetically modified mouseCancer researchTransgeneImmunologyT-cell receptorMajor histocompatibility complexAntigenIn vitroGenetics
DOInot available

Abstract

fetched live from OpenAlex

4252 Many human cancers elicit immune recognition but are nevertheless able to persist and disseminate in immunocompetent individuals. Our goal is to characterize the immune response to spontaneously developing mammary tumors and define the mechanisms by which tumors evade rejection by tumor-specific T cells. We have developed a novel transgenic mouse mammary tumor model in which tumor formation is driven by expression of a modified version of HER2/neu. The modified oncogene, designated neuOTI/OTII, was created by addition of CD8+ (OT-I) and CD4+ (OT-II) T cell epitopes from ovalbumin to the C-terminus of HER2/neu. These epitope tags allow neuOTI/OTII to be recognized by T cell receptor (TCR) transgenic CD8+ and CD4+ T cells specific for these epitopes. Such T cells can be labeled and infused into mice expressing neuOTI/OTII, thereby allowing precise monitoring of CD4+ and CD8+ T cell responses to both established and developing mammary tumors. Transgenic mice expressing neuOTI/OTII together with a dominant-negative p53 transgene (DNp53) develop spontaneous mammary carcinomas at 7-10 months of age with an average latency of 8 months. NeuOTI/OTII is strongly expressed in tumors but not in any other tissues examined. Tumors and derived cell lines are positive for MHC Class I and negative for MHC Class II, Fas, FasL and the costimulatory molecules, B7-1 and B7-2. As expected, CD8+ (OT-I) and CD4+ (OT-II) T cells become activated in vitro when exposed to cells expressing neuOTI/OTII. To study the T cell response to spontaneously arising tumors, naive OT-I or OT-II TCR-transgenic T cells were labeled with the fluorescent dye CFSE and adoptively transferred into tumor-bearing neuOTI/OTII x DNp53 mice. At serial time points, T cell proliferation was evaluated by monitoring reduction in CFSE intensity. T cells were also analyzed for expression of cell surface activation markers. In 5/5 mice that received OT-II cells, little or no proliferation was observed in response to neuOTI/OTII x DNp53 tumors, even as late as 13 days post transfer. In 1/1 mouse that received OT-I and OT-II T cells together, OT-I cells began proliferating within 3 days while OT-II cells remained unresponsive. Unexpectedly, tumor progression stabilized within 4 days of T cell infusion and complete tumor regression had occurred by day 10. These preliminary results suggest that established tumors are capable of triggering a strong, potentially curative, CD8+ response, but appear to selectively evade CD4+ cells. We are currently investigating why OT-II T cells fail to respond to spontaneous neuOTI/OTII x DNp53 tumors as well as the requirements for successful tumor eradication by OT-I T cells.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.004

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.000
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0010.000
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0010.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.083
GPT teacher head0.366
Teacher spread0.283 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2005
Admission routes1
Has abstractyes

Explore more

Same venueCancer Research→Same topicImmunotherapy and Immune Responses→French-language works237,207→